Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
Diabetes, Obesity and Metabolism · 2025-04 · 27 (4) · 1940-1949
DOI: 10.1111/dom.16186 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 09.01.2025. Verfasst von Yu Peng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Major Dise…. Hauptthemen laut MEDLINE: Neoplasms, Fatty Liver. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Tianjin Key Medical Discipline (Specialty) Construction Project.
Abstract (Originalsprache)
Background
Fatty liver disease may be associated with increased risks of intrahepatic and extrahepatic cancers. Our objective was to investigate associations between new subcategories of steatotic liver disease (SLD) recently proposed by nomenclature consensus group and cancer risk.
Methods
A total of 283 238 participants from the UK Biobank were included. Based on information on cardiometabolic factors, alcohol consumption and the specific aetiology of SLD, individuals were categorized into four groups: no SLD ( n = 170 885), metabolic dysfunction‐associated steatotic liver disease (MASLD, n = 74 510), MASLD with increased alcohol intake (MetALD, n = 23 320) and other SLD ( n = 6718). Outcomes were overall incident cancer ( n = 39 352) and 21 site‐specific cancers. The Cox proportional hazards model was used to estimate relationships between subcategories of SLD and cardiometabolic factors in MASLD with cancer risk. Population attributable risk (PAR) of cancer associated with SLD was estimated.
Results
MASLD was the most prevalent SLD in the general population. All SLD subcategories were associated with elevated risks of overall cancer, digestive system cancers (except gastric cancer) and breast cancer (HRs 1.079–4.663). Additionally, MASLD was associated with increased risks of renal cancer, endometrial cancer and Hodgkin lymphoma. Compared to MetALD and other SLDs, MASLD has a higher PAR% for the majority of aforementioned cancers. This could be largely explained by its common metabolic abnormalities, dominantly characterized by overweight/obesity and elevated blood pressure, concomitant with hyperglycaemia and hyperlipidaemia.
Conclusions
All subcategories of SLD, particularly MASLD with multiple metabolic abnormalities, were associated with increased risks of multiple cancers, providing a new perspective for cancer prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Key Laboratory of Prevention and Control of Major Diseases in the Population, Ministry of Education, National Clinical Resea…
- Department of Laboratory Animal Center, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University,…
ORCID-Profile: Fangfang Song
Förderung
- National Key Research and Development Program of China
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Peng, Y., Wang, P., Liu, F., Wang, X., Si, C., Gong, J., Zhou, H., Gu, J., Qin, A., Song, W., & Song, F. (2025). Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study. Diabetes, Obesity and Metabolism, 27(4), 1940-1949. https://doi.org/10.1111/dom.16186
Vancouver
Peng Y, Wang P, Liu F, Wang X, Si C, Gong J, et al. Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study. Diabetes, Obesity and Metabolism. 2025;27(4):1940-1949. doi:10.1111/dom.16186
BibTeX
@article{Peng2025,
author = {Peng, Yu and Wang, Peng and Liu, Fubin and Wang, Xixuan and Si, Changyu and Gong, Jianxiao and Zhou, Huijun and Gu, Jiale and Qin, Ailing and Song, Weijie and Song, Fangfang},
title = {Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {4},
pages = {1940--1949},
doi = {10.1111/dom.16186}
}
EUVIMED